By Date


  • 27-November-2018

    English

    Pharmaceutical Innovation and Access to Medicines

    This report reviews the important role of medicines in health sytems, describes recent trends in pharmaceutical expenditure and financing, and summarises the approaches used by OECD countries to determine coverage and pricing. It then highlights current issues for policy-makers, such as the increasing prices of new medicines; concerns about the value of spending in some therapeutic areas; challenges in anticipating the arrival of very effective medicines for high-prevalent diseases;  sharp price increases in off-patent products; and the apparent misalignment of current incentives for development of treatments for certain conditions. The report also describes the role of the biopharmaceutical industry in OECD economies. It examines the process of pharmaceutical R&D and its financing, then looks at the risks, costs and returms on R&D investment for the pharmaceutical industry. It describes trends in the industry over time, showing that productivity of R&D expenditure has declined, that the duration of market exclusivity has remained relatively stable; that new medicines are increasingly being developed for small patient populations; and that the industry as a whole has remained highly profitable for investors. Lastly, the report presents a range of policy options for consideration by policy makers, to inform the development of effective and coordinated responses to the identified challenges.
  • 16-November-2018

    English

    Long-term care workforce: caring for the ageing population with dignity

    The OECD examines barriers to and policy options for promoting a stronger LTC workforce. Some of the themes analysed include education and training, recruitment and retention, productivity and use of technology, coordination between social and health workers, and coordination between formal and informal workers.

    Related Documents
  • 8-novembre-2018

    Français

    Statistiques de l'OCDE sur la santé 2018

    La base de données Statistiques de l'OCDE sur la santé 2018 représente la source statistique la plus vaste pour comparer les systèmes de santé des pays de l'OCDE. La base de données a été mise à jour le 8 novembre 2018.

    Also AvailableEgalement disponible(s)
  • 8-November-2018

    English, Excel, 4,004kb

    OECD Health Statistics 2018: Frequently Requested Data (Excel file)

    Download this selection of key indicators from OECD Health Statistics 2018, in Excel. Final 2018 version, updated on 8 November 2018.

    Related Documents
  • 7-novembre-2018

    Français

    2 USD par personne et par an suffiraient pour mettre un terme à la résistance aux antimicrobiens

    Les infections à « superbactéries » pourraient tuer quelque 2.4 millions de personnes en Europe, en Amérique du Nord et en Australie au cours des 30 prochaines années si l’on ne redouble pas d’efforts pour enrayer l’antibiorésistance.

    Documents connexes
  • 7-November-2018

    English, PDF, 2,366kb

    Stemming the Superbug Tide - Policy Brief

    This Policy Brief gives an insight to key messages and various highlights from the new OECD report "Stemming the Superbug Tide: Just a Few Dollars More", which analyses the impact of antimicrobial resistance (AMR). The report, based on new forecasts of the growth in resistance to 2050, outlines how countries can tackle AMR and significantly reduce the personal and economic costs.

    Related Documents
  • 7-November-2018

    English

    Stemming the Superbug Tide - Just A Few Dollars More

    Antimicrobial resistance (AMR) is a large and growing problem with the potential for enormous health and economic consequences, globally. As such, AMR has become a central issue at the top of the public health agenda of OECD countries and beyond. In this report, OECD used advanced techniques, including machine learning, ensemble modelling and a microsimulation model, to provide support for policy action in the human health sector. AMR rates are high and are projected to grow further, particularly for second- and third-line antibiotics, and if no effective action is taken this is forecasted to produce a significant health and economic burden in OECD and EU28 countries. This burden can be addressed by implementing effective public health initiatives. This report reviews policies currently in place in high-income countries and identifies a set of ‘best buys’ to tackle AMR that, if scaled up at the national level, would provide an affordable and cost-effective instrument in the fight against AMR.
  • 7-November-2018

    English

    Pharmaceuticals

    Pharmaceuticals have contributed to improvements in life expectancy and quality of life of many patients. Medicines can cure, relieve symptoms, delay the onset of disease and prevent complications. They often offer good value for money. However, recent trends raise a number of concerns.

    Related Documents
  • 7-November-2018

    English

    Public Health

    The OECD work on public health explores major risk factors including obesity, diet, physical activity, alcohol consumption, tobacco and environmental risks, as well as antimicrobial resistance.

  • 7-November-2018

    English

    Antimicrobial Resistance

    Antimicrobial resistance is a growing health and economic threat requiring multipronged responses. The OECD provides a forum for discussion and provide countries with the evidence to implement effective and cost-effective policies to tackle AMR, promote effective use of antimicrobials and incentivise research and development in the antibiotic sector.

  • 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>